OBJECTIVE: To evaluate the potential for statins to treat ovarian cancer. METHODS: The sensitivity of 7 ovarian cancer cell lines to either statins or statins combined with either carboplatin or paclitaxel was assessed using monolayer cultures. Sensitivity to simvastatin was also evaluated in ovarian cancer spheroids. The kinetics of cell death induced by simvastatin was evaluated by measuring Trypan Blue exclusion. Autophagy induced by simvastatin was assessed by measuring LC3-II, p62 or Rab7 by immunoblotting or immunocytochemistry. RESULTS: All statins except pravastatin demonstrated single agent activity against monolayers (IC50=1-35 μM) and spheroids (IC50=1-13 μM). This was mediated by HMG-CoAR inhibition, because either mevalonate or geranylgeraniol prevented the cytotoxic effects of simvastatin. Continuous exposure for 4 days was necessary to cause cell death. Simvastatin caused accumulation of p62 but loss of Rab7, suggesting inhibition of autophagosome trafficking. Accumulation of LC3-II was also observed, even in the presence of bafilomycin, suggesting additional stimulation of an earlier step in autophagy. Knockdown of the key autophagy regulator Atg5 caused a modest increase in the sensitivity of Ovcar-8 cells to simvastatin. Finally, additive or mild antagonist effects were observed when simvastatin was combined simultaneously with either carboplatin or paclitaxel, but when cells were exposed to simvastatin prior to carboplatin, profound antagonism was observed. CONCLUSIONS: These observations suggest that clinical trials of statins in ovarian cancer should evaluate high doses and schedules that ensure continual inhibition of HMG-CoAR. Simvastatin has conflicting effects on the autophagy pathway and this may contribute to its cytotoxic activity.
OBJECTIVE: To evaluate the potential for statins to treat ovarian cancer. METHODS: The sensitivity of 7 ovarian cancer cell lines to either statins or statins combined with either carboplatin or paclitaxel was assessed using monolayer cultures. Sensitivity to simvastatin was also evaluated in ovarian cancer spheroids. The kinetics of cell death induced by simvastatin was evaluated by measuring Trypan Blue exclusion. Autophagy induced by simvastatin was assessed by measuring LC3-II, p62 or Rab7 by immunoblotting or immunocytochemistry. RESULTS: All statins except pravastatin demonstrated single agent activity against monolayers (IC50=1-35 μM) and spheroids (IC50=1-13 μM). This was mediated by HMG-CoAR inhibition, because either mevalonate or geranylgeraniol prevented the cytotoxic effects of simvastatin. Continuous exposure for 4 days was necessary to cause cell death. Simvastatin caused accumulation of p62 but loss of Rab7, suggesting inhibition of autophagosome trafficking. Accumulation of LC3-II was also observed, even in the presence of bafilomycin, suggesting additional stimulation of an earlier step in autophagy. Knockdown of the key autophagy regulator Atg5 caused a modest increase in the sensitivity of Ovcar-8 cells to simvastatin. Finally, additive or mild antagonist effects were observed when simvastatin was combined simultaneously with either carboplatin or paclitaxel, but when cells were exposed to simvastatin prior to carboplatin, profound antagonism was observed. CONCLUSIONS: These observations suggest that clinical trials of statins in ovarian cancer should evaluate high doses and schedules that ensure continual inhibition of HMG-CoAR. Simvastatin has conflicting effects on the autophagy pathway and this may contribute to its cytotoxic activity.
Authors: Laura Friggeri; Tatiana Y Hargrove; Zdzislaw Wawrzak; F Peter Guengerich; Galina I Lepesheva Journal: J Med Chem Date: 2019-11-11 Impact factor: 7.446
Authors: Mohammed Habis; Kristen Wroblewski; Michael Bradaric; Nadia Ismail; S Diane Yamada; Lacey Litchfield; Ernst Lengyel; Iris L Romero Journal: PLoS One Date: 2014-08-13 Impact factor: 3.240
Authors: Jessica E Stine; Hui Guo; Xiugui Sheng; Xiaoyun Han; Monica N Schointuch; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump Journal: Oncotarget Date: 2016-01-05